Efficacy of Leucine rich alfa2 glycoprotein (LRG) as a biomarker in patients with diffuse lung disease

Efficacy of Leucine rich alfa2 glycoprotein (LRG) as a biomarker in patients with diffuse lung disease - Efficacy of Leucine rich alfa2 glycoprotein (LRG) in patients with diffuse lung disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029019

Enrollment

200

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with diffuse lung disease

Exclusion criteria

Exclusion criteria: Cases that can not cooperate with the examination conducted in this study Cases with other respiratory diseases such as lung cancer and non-tuberculous mycobacteria Cases in which consent has not been obtained for this research Case judged by the attending physician to be unqualified

Design outcomes

Primary

Measure	Time frame
Whether LRG become the biomarker for disease differentiation and activity of disease	—

Secondary

Measure	Time frame
Whether LRG become the biomarker for effect of treatment and prediction of prognosis	—

Countries

Japan

Contacts

Public ContactKazufumi Takamatsu

kochi Medical School, Kochi University Department of Hematology and Respiratory Medicine

jm-ktakamatsu@kochi-u.ac.jp088-880-2345

Outcome results